Respiratory events associated with concomitant opioid and sedative use among Medicare beneficiaries with chronic obstructive pulmonary disease

• Published in: BMJ open respiratory research Vol. 7; no. 1; p. e000483
• Main Authors: Le, Tham Thi, Park, Siyeon, Choi, Michelle, Wijesinha, Marniker, Khokhar, Bilal, Simoni-Wastila, Linda
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.03.2020; BMJ Publishing Group
• Subjects: Aged; Aged, 80 and over; Analgesics, Opioid - adverse effects; Anesthesia; Beneficiaries; Chronic Obstructive Pulmonary Disease; Disease; Dyspnea; Emergency Service, Hospital; Epidemiology; Female; Hospitalization; Humans; Hypnotics and Sedatives - adverse effects; Male; Medicare; Mental disorders; Morphine; Narcotics; Older people; Pain; Prescriptions; Propensity Score; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - epidemiology; Pulmonary Disease, Chronic Obstructive - mortality; Respiratory Insufficiency - chemically induced; Respiratory system; Retrospective Studies; Risk; Treatment Outcome; United States - epidemiology; Variables; United States; COPD epidemiology; COPD exacerbations
• ISSN: 2052-4439; 2052-4439
• DOI: 10.1136/bmjresp-2019-000483

BackgroundOpioids and sedatives are commonly prescribed in chronic obstructive pulmonary disease (COPD) patients for symptoms of dyspnoea, pain, insomnia, depression and anxiety. Older adults are advised to avoid these medications due to increased adverse events, including respiratory events. This study examines respiratory event risks associated with concomitant opioid and sedative use compared with opioid use alone in older adults with COPD.MethodsA 5% nationally representative sample of Medicare beneficiaries with COPD and opioid use between 2009 and 2013 was used for this retrospective cohort study. Current and past concomitant use were identified using drug dispensed within 7 days from the censored date: at respiratory event, at death, or at 12 months post index. Concomitant opioid and sedative use were categorised into no overlap (opioid only), 1 to 10, 11 to 30, 31 to 60 and >60 days of total overlap. The primary outcome was hospitalisation or emergency department (ED) visits for respiratory events (COPD exacerbations or respiratory depression). Propensity score matching was implemented and semi-competing risk models were used to address competing risk by death.ResultsAmong 48 120 eligible beneficiaries, 1810 (16.7%) concomitant users were matched with 9050 (83.3%) opioid only users. Current concomitant use of 1 to 10, 11 to 30 and 31 to 60 days was associated with increased respiratory events (HRs (95% CI): 2.8 (1.2 to 7.3), 9.3 (4.9 to 18.2) and 5.7 (2.5 to 12.5), respectively), compared with opioid only use. Current concomitant use of >60 days or past concomitant use of ≤60 days was not significantly associated with respiratory events. Consistent findings were found in sensitivity analyses, including in subgroup analysis of non-benzodiazepine sedatives. Additionally, current concomitant use significantly increased risk of death.ConclusionShort-term and medium-term current concomitant opioid and sedative use significantly increased risk of respiratory events and death in older COPD Medicare beneficiaries. Long-term past concomitant users, however, demonstrated lower risks of these outcomes, possibly reflecting a healthy user effect or developed tolerance to the effects of these agents.